INTRODUCTION
Because two related pentapeptides, methionine-and leucine-enkephalin (Met-and Leu-enkephalin, respec-tively)l were identified as endogenous opioid substances (1), evidence has accumulated suggesting that they function as neurotransmitter or neuromodulator in the central nervous system (2) . Recent reports have shown that enkephalin-like peptides are widely distributed in peripheral tissues, such as sympathetic ganglia, adrenal glands, and the gut (3) (4) (5) (6) (7) . Furthermore, multiple molecular forms of enkephalin-like peptides were detected in bovine adrenal gland, either by radioimmunoassay (RIA) or radioreceptor assay in combination with chromatographic methods (8, 9) . In addition to the heterogeneity in molecular size, the contents of enkephalin-like peptides have been shown to vary from species to species, especially in the adrenal gland (10) .
Recently, Met-and Leu-enkephalin have been demonstrated to exist in human plasma (11, 12) , and the sympathoadrenal system, especially adrenal medulla, is supposed to be the source of plasma enkephalins. However, little is known about enkephalin-like peptides in human sympathoadrenal system except the preliminary finding about Met-enkephalin-like material in the adrenal medulla and pheochromocytoma (11, 13, 14) .
This study was designed to investigate Met-and Leu-enkephalin in human sympathoadrenal systern and pheochromocytoma by sensitive RIA for Met-and Leu-enkephalin in combination with reverse-phase high-performance liquid chromatography (HPLC).
METHODS
RIA. Synthetic Met-, Leu-enkephalin, a-endorphin, and "y-endorphin were generously provided by Daiichi Phar-I Abbreviations used in this paper: HPLC, high-performance liquid chromatography; Leu-enkephalin, leucineenkephalin; Leu-enkephalin-LI, leucine-enkephalin-like immunoreactivity; Met-enkephalin, methionine-enkephalin; Met-enkephalin-LI, methionine-enkephalin-like immunoreactivity; RIA, radioimmunoassay. Fig. 1A and B. The cross-reactivities of the antisera (MC3-1210 and LC2-1210) with related peptides were given in Fig. 1A Leu-enkephalin. The usable range of standard curves is from 5 to 1,000 pg in both RIA. The intra-and interassay coefficients of variation of Met-enkephalin RIA were 2.9 and 11.2%, respectively, while those of Leu-enkephalin RIA were 6.4 and 6.6%, respectively.
On a molar basis the MC3-1210 showed a cross-reactivity of 10 .3% with Leu-enkephalin, whereas it had not significant cross-reactivity with f-endorphin, 6-endorphin, y-endorphin, a-endorphin, and dynorphin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (Table I ).
The LC2-1210 had a cross-reactivity of 12.6% with Met-enkephalin, while it reacted very little with dynorphin (1-13), j3-endorphin, 6-endorphin, y-endorphin, or a-endorphin (Table I) .
The dilution curves of extracts from adrenal glands, adrenal medulla, sympathetic ganglia, and pheochromocytomas were parallel with standard curves of Met-and Leu-enkephalin as shown in Fig. 2A and B.
Because the dilution curves of standard Met-and Leu-enkephalin were closely parallel to each other as shown in Fig. lA Fig. 3 . Met-and Leu-enkephalin contents of HPLC fractions corresponding to the elution positions of synthetic Met-and Leu-enkephalin were determined (Table II) . Although significant amounts of Met-and Leu-enkephalin were present throughout the sympathoadrenal system, the contents of both peptides were highest in the adrenal medulla.
The mean ratios of Met-to Leu-enkephalin in adrenal glands (n = 3) and adrenal medulla (n = 5) were 2.8 and 2.6, respectively. On the other hand, ratios in each sympathetic trunk, stellate ganglia, and celiac ganglia ranged from 4.9 to 11.8.
Met-enkephalin in adrenal glands (n = 3) and adrenal medulla (n = 5) represented -75.9 and 73.7% of Met-enkephalin-LI, while Leu-enkephalin was -20.8 and 29.8% of Leu-enkephalin-LI, respectively.
Pheochromocytomas. The amounts of Met-enkephalin-LI and Leu-enkephalin-LI in two extramedullary and two medullary pheochromocytomas are given in Table II . The amounts of Met-enkephalin-LI and Leu-enkephalin-LI in medullary tumors were three orders higher than those in extramedullary tumors. The contents of Met-enkephalin-LI and Leu-enkephalin-LI in extramedullary tumors were compatible with those in sympathetic ganglia, whereas the contents of Met-enkephalin-LI and Leu-enkephalin-LI in medullary tumors were one order higher than those in adrenal medulla.
HPLC patterns of extracts of two extramedullary and two medullary tumors are depicted in Fig. 4 . In all extracts there existed two peaks of immunoreactivities with identical retention times to those of synthetic Met-and Leu-enkephalin. The contents of Met-and Leu-enkephalin in pheochromocytomas are shown in Table II . The amounts of Met-and Leu-enkephalin in medullary tumors were one order higher than that of adrenal medulla.
The ratios of Met-to Leu-enkephalin in two medullary tumors were 3.0 and 2.9, while those in two extramedullary tumors were 7.6 and 10.4. The ratios in medullary tumors were similar to those in adrenal glands and adrenal medulla, while the ratios in extramedullary tumors were also comparable to those in sympathetic ganglia.
-In medullary pheochromocytoma Met-and Leu-enkephalin were -88.2% of Met-enkephalin-LI and 46.8% of Leu-enkephalin-LI, respectively, while in extramedullary tumors they were 86.7 and 12.7%, respectively. 
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DISCUSSION
To elucidate the physiological significance of enkephalins in human sympathoadrenal system, the precise contents of Met-and Leu-enkephalin in these tissues should be determined because marked species difference in contents of enkephalin-like substances in the sympathoadrenal system has been reported (10). In the RIA for enkephalins, however, cross-reactivities of other enkephalin and related peptides are inevitable due to the resemblance in structure. In our RIA for Met-and Leu-enkephalin, there were cross-reactivities of -10% to each other. Taking these cross-reactivities into account, we calculated Met-and Leu-enkephalin-LI by resolving the equations based on the observations that dilution curves of standard Met-and Leu-enkephalin, as well as tissue extracts, were parallel, and that cross-reactivities of other known related peptides were minimal. A similar analysis was reported by Gros et al. (17) . Because it is difficult to obtain fresh samples from normal human tissues without apparent postmortem proteolysis, sampling conditions are also critical to measure the contents of enkephalins in sympathoadrenal system. In this study specimens at autopsy within 3 h after death were chosen as possible fresh samples. Our study has demonstrated that both Met-and Leuenkephalin-LI exist in human sympathoadrenal system. The content of Met-enkephalin-LI in human adrenal medulla was comparable to that reported preliminarily by Clement-Jones et al. (11) and about four times lower than that of bovine adrenal medulla (10) . Such difference may be explained by species difference. It may be caused by different RIA systems because multiple molecular forms of enkephalin-like peptides cross-react differently with different antisera.
The existence of Leu-enkephalin-LI was previously shown in bovine adrenal glands (8, 10) but not in human adrenal glands (14) when studied by an immunohistochemical method. We adrenal glands. In addition, both Met-and Leu-enkephalin-LI were shown to exist in stellate and celiac ganglia and sympathetic trunks. Their contents were lower than those of reported (6) corresponding tissues in Wistar Kyoto rats. The finding that Met-and Leuenkephalin contents were parallel in each specimen are consistent with the recent finding of Lewis et al. (9) that there exists a common precursor of Met-and Leu-enkephalin with a mol wt of -50,000 in bovine adrenal gland.
To demonstrate the existence of Met-and Leu-enkephalin more clearly, we used HPLC analysis. The analysis showed that Met-enkephalin measured after the chromatography was -74% of Met-enkephalin-LI and that Leu-enkephalin was '.30% of Leu-enkephalin-LI. This discrepancy could be accounted for by different cross-reactivities of possible enkephalin precursors with two antisera. Similar observation that high molecular weight forms occupied -70% of enkephalin-like immunoreactivity in bovine adrenal gland was made by Hexum et al. (10) . Recently we have detected dynorphin-like immunoreactivity by RIA for dynorphin (1-13), one of Leu-enkephalin-containing peptides, in human sympathoadrenal system (18) . The result indicates the existence of high molecular weight forms of Leu-enkephalin.
The ratios of Met-to Leu-enkephalin in human adrenal glands and adrenal medulla were 2 to 3, whereas those in bovine adrenal medulla were reported to range from 5 to 10 (8, 10) . This difference suggests. the possible different posttranslational processing of the enkephalin precursor between the species. The ratio of Met-to Leu-enkephalin in human sympathetic ganglia was higher than that of adrenal glands. This result again suggests that the processing varies in different regions of sympathoadrenal system. These differences in absolute and relative amounts of Met-and Leu-enkephalin between sympathetic nervous system and adrenal medulla suggest their different physiological significance in these tissues.
Recently Met-and Leu-enkephalin have been demonstrated to exist in canine and human plasma (11, 12) , and shown to be released into blood stream in response to the adrenomedullary stimulation (12, 19) . At present, adrenal glands are considered to be the source of plasma enkephalins. High contents of Met-and Leu-enkephalin in human adrenal medulla elucidated in this study are consistent with this hypothesis and suggest possible role of adrenal enkephalins as hormones.
Previous studies have shown that Met-enkephalin-LI is present in pheochromocytoma in a large amount (13, 20) . On the other hand Leu-enkephalin-LI has not been demonstrated to exist by either RIA (20) or immunohistochemistry (14) . We have clearly demonstrated the presence of Leu-enkephalin-LI as well as Met-enkephalin-LI in pheochromocytoma and also identified the occurence of authentic Met-and Leuenkephalin by HPLC. Recently we have also demonstrated the presence of dynorphin in pheochromocytoma (21) . These results indicate that pheochromocytomas elaborate Met-and Leu-enkephalin as well as their possible precursors.
The most interesting finding in our study is a marked difference in enkephalin contents between medullary and extramedullary pheochromocytomas. The concentrations of Met-and Leu-enkephalin in medullary tumors were about three orders higher than those of Metand Leu-enkephalin in extramedullary tumors. The difference might reflect the origin of tumors because similar difference in contents has been shown between adrenal medulla and sympathetic ganglia.
The ratios of Met-to Leu-enkephalin in two medullary pheochromocytomas were 2.9 and 3.0, which are similar to the ratios in the normal adrenal gland and adrenal medulla. In extramedullary tumors the ratios were 7.6 and 10.4, which are similar to those in sympathetic ganglia. Therefore, Met-to Leu-enkephalin ratios in medullary and extramedullary pheochromocytomas might also reflect the ratios in tissues where the tumors are derived.
The physiological roles of Met-and Leu-enkephalin in human sympathoadrenal system and the pathophysiological significance of these peptides in pheochromocytoma must await further clarification.
